According to Innoviva's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.1037. At the end of 2023 the company had a P/S ratio of 3.31.
Year | P/S ratio | Change |
---|---|---|
2023 | 3.31 | 18.65% |
2022 | 2.79 | -8.78% |
2021 | 3.06 | -17.99% |
2020 | 3.73 | -32.12% |
2019 | 5.49 | -18.71% |
2018 | 6.76 | 1.54% |
2017 | 6.66 | -23.37% |
2016 | 8.69 | -61.26% |
2015 | 22.4 | -88.51% |
2014 | 195 | -76.79% |
2013 | 841 | 4661.18% |
2012 | 17.7 | -79.28% |
2011 | 85.2 | 2.48% |
2010 | 83.2 | 141.46% |
2009 | 34.4 | 22.12% |
2008 | 28.2 | -47.9% |
2007 | 54.1 | -42.93% |
2006 | 94.9 | 14.16% |
2005 | 83.1 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
OPKO Health
OPK | 0.9686 | -68.79% | ๐บ๐ธ USA |
Onconova Therapeutics ONTX | 93.9 | 2,924.29% | ๐บ๐ธ USA |